Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacovigilance01:19

Pharmacovigilance

1.9K
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
1.9K
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

503
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
503
Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

674
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
674
Analysis of Population Pharmacokinetic Data01:12

Analysis of Population Pharmacokinetic Data

872
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
872
Model Approaches for Pharmacokinetic Data: Distributed Parameter Models01:06

Model Approaches for Pharmacokinetic Data: Distributed Parameter Models

299
Pharmacokinetic models are mathematical constructs that represent and predict the time course of drug concentrations in the body, providing meaningful pharmacokinetic parameters. These models are categorized into compartment, physiological, and distributed parameter models.
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
299
Kaplan-Meier Approach01:24

Kaplan-Meier Approach

663
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
663

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Identifying anaphylaxis using weakly-supervised prediction models and natural language processing.

medRxiv : the preprint server for health sciences·2026
Same author

Public Perceptions of Ankyloglossia on Reddit: A Cross-Sectional Thematic and Sentiment Analysis.

Laryngoscope investigative otolaryngology·2026
Same author

Predicting and differentiating accidental and self-harm drug poisonings using health records data.

PLOS mental health·2026
Same author

Cost-Effectiveness of Remote Cognitive Behavioral Based Therapy for Chronic Pain among People with High-Impact Chronic Pain.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2026
Same author

Substitution Patterns After Discontinuation of CNS-Active Medications in Older Adults in Primary Care.

Journal of the American Geriatrics Society·2026
Same author

Effect of self-management interventions on high impact chronic pain prevalence.

The journal of pain·2026

Related Experiment Video

Updated: Mar 1, 2026

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
06:55

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

15.4K

Estimating Risk Differences Using Large Healthcare Data Networks for Medical Product Post-Market Safety Outcomes in a

Andrea J Cook1,2, Robert D Wellman1, Tracey Marsh3

  • 1Division of Biostatistics, Kaiser Permanente Washington Health Research Institute, Seattle, Washington, USA.

Statistics in Medicine
|February 27, 2026
PubMed
Summary
This summary is machine-generated.

This study introduces a new method for analyzing rare safety events in medical products using distributed healthcare data. The approach improves risk difference estimation in post-market surveillance, enhancing patient safety monitoring.

Keywords:
distributed datagroup sequentialinverse probability of treatment weightingobservationalpost‐market surveillancevaccine safety

More Related Videos

An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

2.7K
Implementation of a Real-Time Psychosis Risk Detection and Alerting System Based on Electronic Health Records using CogStack
07:31

Implementation of a Real-Time Psychosis Risk Detection and Alerting System Based on Electronic Health Records using CogStack

Published on: May 15, 2020

8.2K

Related Experiment Videos

Last Updated: Mar 1, 2026

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
06:55

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

15.4K
An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

2.7K
Implementation of a Real-Time Psychosis Risk Detection and Alerting System Based on Electronic Health Records using CogStack
07:31

Implementation of a Real-Time Psychosis Risk Detection and Alerting System Based on Electronic Health Records using CogStack

Published on: May 15, 2020

8.2K

Area of Science:

  • Pharmacovigilance and Pharmacoepidemiology
  • Biostatistics and Statistical Methodology
  • Health Data Science

Background:

  • Post-market surveillance of medical products often uses relative risk measures, which are unstable for rare safety events.
  • Existing methods struggle with rare events and data privacy constraints in distributed healthcare networks.
  • Accurate estimation of excess safety risk is crucial for medical product decision-making.

Purpose of the Study:

  • To develop and evaluate a novel statistical method for estimating risk differences in rare event settings within distributed healthcare networks.
  • To address the limitations of relative measures and data sharing restrictions in active post-market safety surveillance.
  • To provide a robust approach for comparing the safety profiles of medical products.

Main Methods:

  • Proposed an inverse probability of treatment weighting (IPTW) method using site-specific propensity scores to estimate stratified risk differences.
  • Extended the stratified IPTW approach for active surveillance by incorporating group sequential monitoring boundaries via a novel permutation approach.
  • Conducted a simulation study to assess method performance and applied it to FDA Sentinel data comparing vaccine safety.

Main Results:

  • The proposed stratified IPTW method demonstrated effectiveness in the rare event setting, requiring minimal data sharing.
  • The group sequential extension is suitable for active post-market surveillance, offering stable estimates over time.
  • The method was successfully applied to real-world safety data, comparing febrile seizure risk between two vaccines.

Conclusions:

  • The novel stratified IPTW method provides a reliable and privacy-preserving approach for estimating risk differences in rare event safety surveillance.
  • This method enhances the ability to detect and assess excess safety risks of medical products in distributed healthcare networks.
  • The findings support improved decision-making in post-market drug and vaccine safety monitoring.